Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Dendreon Provenge Plant Completion Is Last Hurdle Before BLA Filing

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Decision to move ahead follows talks with FDA suggesting existing data are sufficient for filing, despite failure of one of two pivotal trials.

You may also be interested in...



Dendreon Submits Rolling BLA For Provenge Prostate Cancer Vaccine

Company says it is the first to submit a therapeutic cancer vaccine application to FDA.

Dendreon Submits Rolling BLA For Provenge Prostate Cancer Vaccine

Company says it is the first to submit a therapeutic cancer vaccine application to FDA.

Intracel OncoVAX Phase III Will Follow Patients For Three Years

Firm says single pivotal trial of the autologous cancer vaccine can support a BLA for adjuvant treatment of Stage II colon cancer.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA Lab Test Rule Cites Explosion In Companion Diagnostics, COVID Lessons

New ePortal To Simplify Processing & Tracking Of WHO Prequalification Applications

Brazil Publishes Real-World Evidence Guide

Sanofi’s Orbis-Approved GVHD Drug Rezurock Rejected For English Funding

See All
UsernamePublicRestriction

Register

PS062885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By